Pulmonary hypertension: The great leveler

Journal of the American College of Cardiology

Volumn 59, Issue 3, 2012, Pages 232-234

  Park, Myung H ^a   Mehra, Mandeep R ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

community; heart failure; mortality; pulmonary hypertension

Indexed keywords

COMMUNITY ASSESSMENT; COMORBIDITY; DISEASE ASSOCIATION; DISEASE COURSE; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FAILURE; HUMAN; MORTALITY; NOTE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84855674783     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.09.052     Document Type: Editorial

References (15)

1. R.J. Barst, S.R. Gibbs, H.A. Ghofrani Updated evidence-based treatment algorithm in pulmonary arterial hypertension J Am Coll Cardiol 54 Suppl 2009 78 84
2. V.V. McLaughlin, S.L. Archer, D.B. Badesch ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association J Am Coll Cardiol 53 2009 1573 1619
3. M.M. Hoeper, J.A. Barbera, R.N. Channick Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension J Am Coll Cardiol 54 Suppl 2009 85 96
4. W.T. Abraham, M.V. Raynolds, B. Gottschall Importance of angiotensin-converting enzyme in pulmonary hypertension Cardiology 86 Suppl 1 1995 9 15
5. M.R. Bristow, W. Minobe, R. Rasmussen Beta-adrenergic neuroeffector abnormalities in the failing human heart are produced by local rather than systemic mechanisms J Clin Invest 89 1992 803 815
6. P.R. Kalra, J.C. Moon, A.J. Coats Do results of the ENABLE (Endothelin Antagonists Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? Int J Cardiol 85 2002 195 197 (Pubitemid 35245980)
7. G.D. Lewis, J. Lachmann, J. Camuso Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure Circulation 115 2007 59 66 (Pubitemid 46058612)
8. F. Bursi, S.M. McNallan, M.M. Redfield Pulmonary pressures and death in heart failure: a community study J Am Coll Cardiol 59 2012 222 231
9. J. Kjaergaard, D. Akkan, K.K. Iversen Prognostic importance of pulmonary hypertension in patients with heart failure Am J Cardiol 99 2007 1146 1150 (Pubitemid 46578202)
10. C.C. Leung, V. Moondra, E. Catherwood Prevalence and risk factors of pulmonary hypertension in patients with elevated pulmonary venous pressure and preserved ejection fraction Am J Cardiol 106 2010 284 286
11. H. Rosjo, T. Omland New statistical methods for the evaluation of cardiovascular risk markers: what the clinician should know Clin Science 117 2009 13 15
12. C.S. Lam, V.L. Roger, R.J. Rodeheffer Pulmonary hypertension in heart failure with preserved ejection fraction J Am Coll Cardiol 53 2009 1119 1126
13. J.X.J. Yuan, L.J. Rubin Pathogenesis of pulmonary arterial hypertension: the need for multiple hits Circulation 111 2005 534 538 (Pubitemid 40216478)
14. I.M. Robbins, J.H. Newman, R.F. Johnson Association of the metabolic syndrome with pulmonary venous hypertension Chest 136 2009 31 36
15. R.A. Quaife, D. Lynch, D.B. Badesch Right ventricular phenotypic characteristics in subjects with primary pulmonary hypertension or idiopathic dilated cardiomyopathy J Card Fail 5 1999 46 54 (Pubitemid 29149088)